Hamilton Thorne, Inc. Announces Preliminary 2012 Fourth Quarter Financial Results
Published: Feb 12, 2013
BEVERLY, MA and TORONTO--(Marketwire - February 11, 2013) -
"Our preliminary unaudited results show that Hamilton Thorne's fourth quarter sales increased to approximately $2.05 million, up 41% versus the third quarter of 2012 and up 2% versus the same quarter last year," said David Wolf, President and Chief Executive Officer of Hamilton Thorne Ltd. "More importantly, we generated approximately $150,000 of positive cash flow for the quarter due to the combination of strong sales and the full impact of the strategic cost cutting that we executed in the third quarter."
Sales growth was driven by increased demand for the Hamilton Thorne's best-of-class CASA II image analysis systems which were introduced at the end of the third quarter and shipped in quantity in Q4. Total preliminary sales for the year were approximately $6.3 million.
Mr. Wolf continued, "In 2013, we expect to continue to invest in product enhancements and sales and marketing activities, in order to continue our growth trajectory while managing our expenses, and moving Hamilton Thorne towards profitability and positive cash flow."
The financial information contained in this news release is based on management's estimates and is subject to adjustment. The Company expects to release its completed audited financial statements for the year ended December 31, 2012 on or about April 29, 2013.
About Hamilton Thorne Ltd. (www.hamiltonthorne.com)
Hamilton Thorne designs, manufactures and distributes precision laser devices and advanced imaging systems for the fertility, stem cell and development biology research markets. It provides novel solutions for Life Science that reduce cost, increase productivity, improve results and enable research breakthroughs in fertility, regenerative medicine, and stem cell research markets. Hamilton Thorne's laser products attach to standard inverted microscopes and operate as robotic micro-surgeons, enabling a wide array of scientific applications and IVF procedures. Its imaging systems improve outcomes in human IVF clinics and animal breeding facilities, and provide high-end toxicology analyses.
Hamilton Thorne's growing customer base includes pharmaceutical companies, biotechnology companies, fertility clinics, university research centers, and other commercial and academic research establishments worldwide. Current customers include world-leading research labs such as Harvard, MIT, Yale, McGill, DuPont, Monsanto, Charles River Labs, Jackson Labs, Merck, Novartis, Pfizer, and Oxford and Cambridge.
Neither the Toronto Venture Exchange, nor its regulation services provider (as that term is defined in the policies of the exchange), accepts responsibility for the adequacy or accuracy of this release.
Certain information in this press release may contain forward-looking statements. This information is based on current expectations that are subject to significant risks and uncertainties that are difficult to predict. Actual results might differ materially from results suggested in any forward-looking statements. The Company assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements unless and until required by securities laws applicable to the Company. Additional information identifying risks and uncertainties is contained in filings by the Company with the Canadian securities regulators, which filings are available at www.sedar.com.
For more information, please contact:
President and CEO
Hamilton Thorne Ltd.